Azacytidine is named as an intervention in 4 current clinical trials in our China register. 3 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Chinese PLA General Hospital (2). The most-studied condition is Relapsed Peripheral T-Cell Lymphomas.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia
NCT07514936 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Elderly Patients
|
Phase 3 | Recruiting | Chinese PLA General Hospital | China |
|
A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients
NCT06928376 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, First Line Therapy
|
Phase 2 | Recruiting | Chinese PLA General Hospital | China |
|
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas
NCT06176027 · ClinicalTrials.gov ↗ · Relapsed Peripheral T-Cell Lymphomas, Refractory Peripheral T-Cell Lymphomas
|
Phase 1/2 | Recruiting | Navy General Hospital, Beijing | China |
|
AZA Combined with R-GemOx for Elderly DLBCL Patients
NCT06778902 · ClinicalTrials.gov ↗ · DLBCL - Diffuse Large B Cell Lymphoma
|
Phase 2 | Not yet open | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Chinese PLA General Hospital | 2 |
| Navy General Hospital, Beijing | 1 |
| Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 4 | 3 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China register name Azacytidine as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 4 trials are recruiting: 3 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Chinese PLA General Hospital (2), Navy General Hospital, Beijing (1) and Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Azacytidine works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Azacytidine works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Azacytidine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.